RT Journal Article
SR Electronic
T1 International Union of Pharmacology XXXVII. Nomenclature for Leukotriene and Lipoxin Receptors
JF Pharmacological Reviews
JO Pharmacol Rev
FD American Society for Pharmacology and Experimental Therapeutics
SP 195
OP 227
DO 10.1124/pr.55.1.8
VO 55
IS 1
A1 Charles Brink
A1 Sven-Erik Dahlén
A1 Jeffrey Drazen
A1 Jilly F. Evans
A1 Douglas W. P. Hay
A1 Simonetta Nicosia
A1 Charles N. Serhan
A1 Takao Shimizu
A1 Takehiko Yokomizo
YR 2003
UL http://pharmrev.aspetjournals.org/content/55/1/195.abstract
AB The leukotrienes and lipoxins are biologically active metabolites derived from arachidonic acid. Their diverse and potent actions are associated with specific receptors. Recent molecular techniques have established the nucleotide and amino acid sequences and confirmed the evidence that suggested the existence of different G-protein-coupled receptors for these lipid mediators. The nomenclature for these receptors has now been established for the leukotrienes. BLT receptors are activated by leukotriene B4 and related hydroxyacids and this class of receptors can be subdivided into BLT1 and BLT2. The cysteinyl-leukotrienes (LT) activate another group called CysLT receptors, which are referred to as CysLT1 and CysLT2. A provisional nomenclature for the lipoxin receptor has also been proposed. LXA4 and LXB4 activate the ALX receptor and LXB4 may also activate another putative receptor. However this latter receptor has not been cloned. The aim of this review is to provide the molecular evidence as well as the properties and significance of the leukotriene and lipoxin receptors, which has lead to the present nomenclature.